OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIZIDE

Olmesartan Medoxomil And Hydrochlorothizide Adverse Events Reported to the FDA Over Time

How are Olmesartan Medoxomil And Hydrochlorothizide adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Olmesartan Medoxomil And Hydrochlorothizide, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Olmesartan Medoxomil And Hydrochlorothizide is flagged as the suspect drug causing the adverse event.

Most Common Olmesartan Medoxomil And Hydrochlorothizide Adverse Events Reported to the FDA

What are the most common Olmesartan Medoxomil And Hydrochlorothizide adverse events reported to the FDA?

Hypertensive Emergency	31 (4.17%)
Death	20 (2.69%)
Chest Pain	17 (2.29%)
Blood Pressure Increased	15 (2.02%)
Dyspnoea	15 (2.02%)
Drug Ineffective	13 (1.75%)
Headache	13 (1.75%)
Leukocyturia	12 (1.62%)
Obesity	12 (1.62%)
Renal Failure Chronic	12 (1.62%)
Angiopathy	11 (1.48%)
	Show More
Haematuria	11 (1.48%)
Cerebrovascular Accident	10 (1.35%)
Pain In Extremity	9 (1.21%)
Cardiac Disorder	8 (1.08%)
Completed Suicide	8 (1.08%)
Hypokalaemia	8 (1.08%)
Malaise	8 (1.08%)
Cough	7 (.94%)
Tobacco Abuse	7 (.94%)
Vomiting	7 (.94%)
Dyspnoea Exertional	6 (.81%)
Fall	6 (.81%)
Gait Disturbance	6 (.81%)
Oedema Peripheral	6 (.81%)
Palpitations	6 (.81%)
Renal Failure Acute	6 (.81%)
Acute Myocardial Infarction	5 (.67%)
Asthenia	5 (.67%)
Condition Aggravated	5 (.67%)
Diarrhoea	5 (.67%)
Exercise Lack Of	5 (.67%)
Gastritis	5 (.67%)
Urinary Tract Infection	5 (.67%)
Abdominal Pain Upper	4 (.54%)
Accident	4 (.54%)
Angina Pectoris	4 (.54%)
Dehydration	4 (.54%)
Fatigue	4 (.54%)
Glycosuria	4 (.54%)
Hypercalcaemia	4 (.54%)
Hyponatraemia	4 (.54%)
Joint Dislocation	4 (.54%)
Joint Injury	4 (.54%)
Lower Limb Fracture	4 (.54%)
Myocardial Infarction	4 (.54%)
Pain	4 (.54%)
Transaminases Abnormal	4 (.54%)
Treatment Noncompliance	4 (.54%)
Weight Increased	4 (.54%)
Anaemia	3 (.4%)
Angina Unstable	3 (.4%)
Angioplasty	3 (.4%)
Arthritis	3 (.4%)
Blood Cholesterol Increased	3 (.4%)
Blood Pressure Decreased	3 (.4%)
Blood Pressure Fluctuation	3 (.4%)
Cardiac Failure	3 (.4%)
Dizziness	3 (.4%)
Erythema	3 (.4%)
Hyperkalaemia	3 (.4%)
Hypersensitivity	3 (.4%)
Hypertension	3 (.4%)
Hypertensive Crisis	3 (.4%)
Incontinence	3 (.4%)
Influenza	3 (.4%)
Leukocytoclastic Vasculitis	3 (.4%)
Nausea	3 (.4%)
Sudden Cardiac Death	3 (.4%)
Abortion Induced	2 (.27%)
Anxiety	2 (.27%)
Back Pain	2 (.27%)
Blood Parathyroid Hormone Increased	2 (.27%)
Blood Pressure Abnormal	2 (.27%)
Blood Pressure Systolic Increased	2 (.27%)
Bradycardia	2 (.27%)
Burning Sensation	2 (.27%)
Cardiac Arrest	2 (.27%)
Cardiac Valve Disease	2 (.27%)
Colitis	2 (.27%)
Colitis Microscopic	2 (.27%)
Crystalluria	2 (.27%)
Disorientation	2 (.27%)
Drug Exposure During Pregnancy	2 (.27%)
Drug Interaction	2 (.27%)
Drug Rash With Eosinophilia And Sys...	2 (.27%)
Erysipelas	2 (.27%)
Eye Haemorrhage	2 (.27%)
Feeling Of Despair	2 (.27%)
Generalised Oedema	2 (.27%)
Haemodynamic Instability	2 (.27%)
Hypercholesterolaemia	2 (.27%)
Hyperhidrosis	2 (.27%)
Hypotension	2 (.27%)
Influenza Like Illness	2 (.27%)
Intermittent Claudication	2 (.27%)
Interstitial Lung Disease	2 (.27%)
Loss Of Consciousness	2 (.27%)
Myalgia	2 (.27%)
Neoplasm	2 (.27%)
Oedema	2 (.27%)

Share/Embed Graph Export Data

This graph shows the top adverse events submitted to the FDA for Olmesartan Medoxomil And Hydrochlorothizide, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Olmesartan Medoxomil And Hydrochlorothizide is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Olmesartan Medoxomil And Hydrochlorothizide

What are the most common Olmesartan Medoxomil And Hydrochlorothizide adverse events reported to the FDA?

Urinary Tract Signs	37 (4.98%)
Vascular Hypertensive	37 (4.98%)
Respiratory	36 (4.85%)
Cardiac And Vascular Investigations	23 (3.1%)
Fatal Outcomes	23 (3.1%)
Renal Disorders	23 (3.1%)
Epidermal And Dermal Conditions	21 (2.83%)
Electrolyte And Fluid Balance Condi...	19 (2.56%)
Coronary Artery	18 (2.42%)
Therapeutic And Nontherapeutic Effe...	18 (2.42%)
Gastrointestinal Signs	16 (2.15%)
	Show More
Neurological	16 (2.15%)
Vascular	16 (2.15%)
Cardiac Disorder Signs	15 (2.02%)
Appetite And General Nutritional	14 (1.88%)
Musculoskeletal And Connective Tiss...	14 (1.88%)
Central Nervous System Vascular	13 (1.75%)
Headaches	13 (1.75%)
Infections - Pathogen Unspecified	13 (1.75%)
Bone And Joint Injuries	12 (1.62%)
Injuries	12 (1.62%)
Lifestyle Issues	11 (1.48%)
Gastrointestinal Inflammatory Condi...	10 (1.35%)
Suicidal And Self-injurious Behavio...	10 (1.35%)
Joint	9 (1.21%)
Cardiac Arrhythmias	8 (1.08%)
Decreased And Nonspecific Blood Pre...	8 (1.08%)
Lower Respiratory Tract Disorders	7 (.94%)
Psychiatric	7 (.94%)
Gastrointestinal Motility And Defec...	6 (.81%)
Lipid Analyses	5 (.67%)
Renal And Urinary Tract Investigati...	5 (.67%)
Viral Infectious	5 (.67%)
Anxiety Disorders	4 (.54%)
Arteriosclerosis, Stenosis, Vascula...	4 (.54%)
Bone, Calcium, Magnesium And Phosph...	4 (.54%)
Chemical Injury And Poisoning	4 (.54%)
Depressed Mood Disorders	4 (.54%)
Heart Failures	4 (.54%)
Hepatobiliary	4 (.54%)
Lipid Metabolism	4 (.54%)
Metabolic, Nutritional And Blood Ga...	4 (.54%)
Muscle	4 (.54%)
Physical Examination Topics	4 (.54%)
Skin Vascular Abnormalities	4 (.54%)
Vascular Therapeutic Procedures	4 (.54%)
Venous Varices	4 (.54%)
Vision	4 (.54%)
Allergic Conditions	3 (.4%)
Anemias Nonhemolytic And Marrow Dep...	3 (.4%)
Bacterial Infectious	3 (.4%)
Body Temperature Conditions	3 (.4%)
Cardiac Valve	3 (.4%)
Endocrine Investigations	3 (.4%)
Glucose Metabolism Disorders	3 (.4%)
Hepatic And Hepatobiliary	3 (.4%)
Medication Errors	3 (.4%)
Myocardial	3 (.4%)
Ocular Hemorrhages And Vascular	3 (.4%)
Oral Soft Tissue Conditions	3 (.4%)
Water, Electrolyte And Mineral	3 (.4%)
Acid-base	2 (.27%)
Deliria	2 (.27%)
Endocrine Neoplasms Malignant And U...	2 (.27%)
Gastrointestinal Ulceration And Per...	2 (.27%)
Hematology Investigations	2 (.27%)
Manic And Bipolar Mood Disorders	2 (.27%)
Miscellaneous And Site Unspecified ...	2 (.27%)
Obstetric And Gynecological Therape...	2 (.27%)
Placental, Amniotic And Cavity Diso...	2 (.27%)
Pregnancy, Labour, Delivery And Pos...	2 (.27%)
Purine And Pyrimidine Metabolism	2 (.27%)
Renal And Urinary Tract Neoplasms M...	2 (.27%)
Sexual Function And Fertility	2 (.27%)
Skin Appendage Conditions	2 (.27%)
Sleep Disorders	2 (.27%)
Therapeutic Procedures And Supporti...	2 (.27%)
Upper Respiratory Tract Disorders	2 (.27%)
Uterine, Pelvic And Broad Ligament	2 (.27%)
Aneurysms And Artery Dissections	1 (.13%)
Angiedema And Urticaria	1 (.13%)
Aural	1 (.13%)
Benign Neoplasms Gastrointestinal	1 (.13%)
Bone And Joint Therapeutic Procedur...	1 (.13%)
Breast Neoplasms Malignant And Unsp...	1 (.13%)
Bronchial Disorders	1 (.13%)
Cranial Nerve Disorders	1 (.13%)
Embolism And Thrombosis	1 (.13%)
Fetal Complications	1 (.13%)
Fungal Infectious	1 (.13%)
Gastrointestinal Conditions	1 (.13%)
Gastrointestinal Hemorrhages	1 (.13%)
Gastrointestinal Neoplasms Malignan...	1 (.13%)
Hematological And Lymphoid Tissue T...	1 (.13%)
Hepatobiliary Therapeutic Procedure...	1 (.13%)
Hypothalamus And Pituitary Gland	1 (.13%)
Impulse Control	1 (.13%)
Inner Ear And Viiith Cranial Nerve	1 (.13%)
Metabolic And Nutritional Disorders...	1 (.13%)
Metabolism	1 (.13%)
Movement Disorders	1 (.13%)

Share/Embed Graph Export Data

This graph shows the top categories of adverse events submitted to the FDA for Olmesartan Medoxomil And Hydrochlorothizide, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Olmesartan Medoxomil And Hydrochlorothizide is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.